CYBORD regimen for multiple myeloma: Velcade, Cytoxan and dexamethasone – pro
The CYBORD regimen is in interesting attempt to combinae Cytoxan with Velcade. A recent phase II trial enrolled thirty-seven patients. At the dose levels defined in the trial, the overall response rate was 95% (complete responses
[CR] plus partial response plus minimal response), with CR observed in more than 50% of patients.
The authors state: “Further evaluation of this promising regimen is warranted both in relapsed and newly diagnosed disease.”
In 2010 ASCO, the was a study presented that compared CyBorD with Revlimid (lenalidomide)-dexamethasone treatment (abbreviated RD) and cyclophosphamide-Revlimid-dexamethasone treatment (abbreviated CRD). The results of the Phase 2 trials indicate that RD and CyBorD treatment were similar in efficacy and safety. CRD, however, was not as effective and had more severe side effects than RD and CyBorD.
NCCN in the section on myeloma therapy lists this regimen for first line.
Victor H Jimenez Zepeda, Peter Duggan, Paola E. Neri and Nizar J Bahlis, Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Is a Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients, Blood 2014 124:5751
Donna E. Reece, Giovanni Piza Rodriguez, Christine Chen, Suzanne Trudel, Vishal Kukreti, Joseph Mikhael,
Mariela Pantoja, Wei Xu, and A. Keith Stewart Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide
and Prednisone in Relapsed and Refractory Multiple Myeloma J Clin Oncol VOLUME 26 NUMBER 28 OCTOBER 1 2008
M. L. Khan, C. B. Reeder, S. Kumar, M. Lacy, D. E. Reece, K. M. Laumann, J. Mikhael, R. Fonseca, V. Rajkumar, A. K. Stewart; Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; University Health Network, Toronto, ON, Canada Comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM). J Clin Oncol 28:15s, 2010 (suppl; abstr 8131)
M. L. Khan, C. B. Reeder, S. Kumar, M. Lacy, D. E. Reece, K. M. Laumann, J. Mikhael, R. Fonseca, V. Rajkumar, A. K. Stewart; Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; University Health Network, Toronto, ON, Canada Comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM). J Clin Oncol 28:15s, 2010 (suppl; abstr 8131)